¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Minimal residual disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
¿µ¹® Wilson's disease ÇÑ±Û Àª½¼º´
¼³¸í   
  °£À̳ª ³ú¿¡ ±¸¸®°¡ ºñÁ¤»óÀûÀ¸·Î ½×¿© ÀϾ´Â À¯Àü¼º ´ë»çº´. °£°æÈ­ÁõÀ̳ª ½Å°æ Áõ»óÀÌ µû¸£´Âµ¥, ¼Õ ¶³¸²À̳ª ¾ð¾î Àå¾Ö°¡ »ý±â°í ´«ÀÇ °¢¸· ÁÖÀ§¿¡ ³ì°¥»ö °í¸®°¡ ³ªÅ¸³­´Ù. ¿µ±¹ÀÇ ½Å°æ°ú ÀÇ»ç Àª½¼(Wilson)ÀÌ ºÐ·ùÇÑ º´ÀÌ´Ù. º¸Åë¿°»öü ¿­¼ºÀ¸·Î À¯ÀüµÈ´Ù. Çѱ¹¿¡¼­µµ ÇöÀç±îÁö 50¿© ¿¹°¡ º¸°íµÇ¾î ÀÖ´Ù. À̺´Àº º¸Åë¿°»öü ¿­¼ºÀ¸·Î À¯ÀüµÇ¸ç, ATP7B¶ó´Â Àª½¼º´ À¯ÀüÀÚ°¡ 13¹ø ¿°»öü¿¡ À§Ä¡ÇÑ´Ù. Æ¯Â¡À¸·Î ±¸¸®°¡ °£, ³ú ¹× °¢¸·¿¡ ÃàÀûÇÏ¿© ¸¸¼º °£¿° ¶Ç´Â °£°æÈ­¿Í °°Àº °£¼Õ»óÀ» ÀÏÀ¸Å°°í, ³ú Æ¯È÷ ·»ÁîÇÙÀÇ ÅðÇà º¯È­¿Í °¢¸·¸ð¼­¸®¿¡ ³ì°¥»öÀÇ Kayser-Fleischer °í¸®¸¦ Çü¼ºÇÑ´Ù. ÀÓ»óÁõ»óÀÇ ¹ßÇöÀº º¸Åë 5~15¼¼¿¡ ½ÃÀÛÇϴµ¥ 30~40¼¼°¡ µÇµµ·Ï Áõ»óÀÌ ¾øÀ» ¼öµµ ÀÖ´Ù.
¿µ¹® hyaline membrane disease ÇÑ±Û À¯¸®Áú¸·º´
¼³¸í   
  ÇãÆÄ ¼º¼÷µµÀÇ ¹Ì¼÷À¸·Î ÇãÆÄ²Ê¸®¸¦ ÆØÃ¢½Ã۴ ¹°Áú(Ç¥¸éȰ¼ºÁ¦)ÀÌ ºÎÁ·ÇÏ¿© È£Èí°ï¶õÀÌ ÃÊ·¡µÇ´Â º´À¸·Î¼­ ¹Ì¼÷¾Æ¿¡ È£¹ßÇϴµ¥, Ãâ»ý½Ã ÀӽűⰣº¸´Ùµµ ÇãÆÄ ¼º¼÷ Á¤µµ°¡ ´õ °ü¿©µÈ´Ù. ´ÜÀÏ º´À¸·Î¼­´Â »ç¸Á·üÀÌ °¡Àå ³ôÀ¸¸ç(¾à 30%), ½Å»ý¾ÆÀÇ ´ëÇ¥ÀûÀΠº´ÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ¹Ì¼÷¾Æ, »ýÈÄ 6~8½Ã°£³» È£Èí°ï¶õÁõ¼¼ ÃâÇö°ú »ýÈÄ 24~48½Ã°£ÀÇ Áõ»ó ¾ÇÈ­, »ýÈÄ 2~3Àϰ£ ÀΰøÀûÀ¸·Î »ê¼Ò¸¦ °ø±ÞÇÏÁö ¾ÊÀ¸¸é È£ÈíÀ» °è¼Ó½Ãų ¼ö°¡ ¾øÀ¸¸ç Á¡Á¡´õ »ê¼ÒÀÇ °ø±Þ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö¸ç, µ¿¸ÆÇ÷¾×¼ÓÀÇ »ê¼Ò³óµµ°¡ ³»·Á°¡°í ÀÌ»êȭź¼ÒÀÇ ³óµµ°¡ ³ôÀ¸¸ç, ÈäºÎ ¹æ»ç¼± ¼Ò°ßÀ» ÂüÀÛÇÏ¿© Áø´ÜÇÑ´Ù. È¯¾Æ´Â ¼÷·ÃµÈ °£È£ Àη°ú Ã·´Ü ÀÇ·á Àåºñ°¡ ¼³Ä¡µÈ ½Å»ý¾Æ ÁýÁß Ä¡·á½Ç¿¡¼­ Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¿¹ÈĴ Áõ¼¼ÀÇ °æÁß¿¡ µû¶ó ´Ù¸£°í »ç¸Á·üÀº 30~50% µÈ´Ù. ¾î¶² ¾Æ±â¿¡ À־´Â Ä¡·á ÈÄ¿¡ ´«À̳ª ±â°üÁöÇãÆÄ °èÅë¿¡ Àå¾Ö¸¦ ÀÏÀ¸Å°´Â »ê¼ÒÁßµ¶ÁõÀÌ º¸°íµÇ°í ÀÖ´Ù.
¿µ¹® fibrocystic disease of breast ÇÑ±Û À¯¹æ ¼¶À¯³¶º´
¼³¸í   
  Á¥À» »ý»êÇϴ Á¥»ù³»¿¡ ¿ÏµÎÄᠶǴ ūÄá Å©±âÀÇ °áÀýÀÌ ¹ß»ýÇϴ Áõ¼¼¸¦ Æ¯Â¡À¸·Î Çϴ º´. 30~50´ëÀÇ ºÎÀο¡°Ô ÈçÈ÷ ¹ß»ýÇϸç, ±× ´ëºÎºÐÀº ¾çÂÊ À¯¹æ¿¡ µ¿½Ã¿¡ ¹ß»ýÇÑ´Ù. ÀÌ·¯ÇÑ °áÀýÀº µÎ ¼Õ°¡¶ô »çÀÌ¿¡ ³¢¿ö ÃËÁøÇÒ ¶§´Â ºÐ¸íÇÏÁö¸¸, È亮À» ¼Õ¹Ù´ÚÀ¸·Î ´©¸£¸é ¸í·áÇÏÁö ¾ÊÀ» Á¤µµ·Î ºÎµå·¯¿î °ÍÀÌ ¸¹´Ù. ±× ¹ß»ý ¿øÀο¡´Â ¿©·¯ °¡Áö ¼³ÀÌ ¸¹Àºµ¥, Á¥»ùÁ¶Á÷¿¡ ´ëÇÑ ¸¸¼ºÀûÀΠÀÚ±ØÀÌ ÁÖ¿øÀÎÀ̶ó »ý°¢µÇ°í ÀÖÀ¸¸ç, ±ØÈ÷ ¼­¼­È÷ ÁøÇàÇϴ °æ°ú¸¦ ¹â´Â´Ù. Áø´ÜÀº ÃËÁø, ÃÊÀ½ÆÄÁø´Ü µîÀ¸·Î Çϸç, ¾Ï°ú °¨º°ÀÌ °ï¶õÇÒ ¶§´Â Á¶Á÷ÀÇ ÀϺθ¦ Ã¤ÃëÇÏ¿© °Ë»çÇϴ »ý°ËÀÌ ÀÌ¿ëµÇ±âµµ ÇÑ´Ù.
¿µ¹® periodontal disease ÇÑ±Û Ä¡ÁÖº´
¼³¸í   
  ÀÕ¸ö°ú Ä¡¾Æ, ±×¸®°í ±× ÁÖÀ§ »ÀÀÇ ¿°Áõ°ú ÅðÇ༺ º¯È­¸¦ ¸»ÇÔ. Ä¡·á¿¡ À־ ÀÕ¸öÀÇ Á¦°Å°¡ ÇʼöÀûÀÌ´Ù. ÀÕ¸öÀÇ Á¦°Å´Â »õ·Î¿î ÀÕ¸öÀÇ »ý¼ºÀ» Á¶ÀåÇÑ´Ù.
¿µ¹® Crohn's disease ÇÑ±Û Å©·Ðº´
¼³¸í   
  ¸¸¼ºÀûÀ̰í Àç¹ßÀ» ÀßÇϴ âÀÚÀÇ ¿°ÁõÀ» Æ¯Â¡À¸·Î Çϴ º´. ÀåÀÇ º®Àº ¾ÈÂÊ¿¡¼­ºÎÅÍ Á¡¸·, Á¡¸·ÇÏÁ¶Á÷, ±ÙÀ°Ãþ, À帷ÀÇ 4°³ÀÇ ÃþÀ¸·Î ÀÌ·ç¾îÁ® Àִµ¥, Å©·Ðº´Àº ÀÌ ¸ðµç ÃþÀÇ ¿°ÁõÀ» µ¿¹ÝÇÑ´Ù. ÀåÀÇ ¸ðµç ºÎºÐ¿¡¼­ »ý±æ ¼ö°¡ ÀÖÁö¸¸ ÁַΠ¸·Ã¢ÀÚ¿Í ¿¬°áµÇ´Â Å«Ã¢ÀÚÀÇ ¸»´ÜºÎ¿¡ °¡Àå ¸¹ÀÌ »ý±ä´Ù. Ã¢ÀÚÀÇ ÀüÃþÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼­ ÀåÀÇ Æó¼â³ª ±«¾çÀ» ¸¸µé¸ç Á¾Á¾ Ãµ°øµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • aviator¡¯s disease
    ºñÇà»çº´
  • acquired cystic kidney disease
    ÈÄõ³¶¼ºÄáÆÏº´, ÈÄõ³¶¼º½ÅÀ庴
  • Addison¡¯s disease
    ¾Öµð½¼º´
  • adult disease
    ¼ºÀκ´
  • Albers-Schonberg disease
    ¾Ëº£¸£½º-¼éº£¸£Å©º´
  • Alexander disease
    ¾Ë·º»ê´õº´
  • alkali disease
    ¾ËÄ®¸®º´
  • allergic disease
    ¾Ë·¹¸£±âº´
  • aluminium dust disease
    ¾Ë·ç¹Ì´½°¡·çº´
  • alveolar hydatid disease
    ²Ê¸®ÇüÆ÷Ãæº´, ´Ù¹æÆ÷Ãæº´
  • Alzheimer disease
    ¾ËÃ÷ÇÏÀ̸Ӻ´
  • Andersen¡¯s disease
    ¾Èµ¥¸£¼¾º´
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • Batten¡¯s disease
    ¹èưº´
  • bauxite fume disease
    º¸Å©»çÀÌÆ®Áõ±âº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • residual valency
    ÀÜ·ù¿øÀÚ°¡
  • residual volume
    Àܱⷮ, ³²Àº°ø±â·®
  • accumulation disease
    ÃàÀûº´
  • acquired cystic kidney disease
    ÈÄõ³¶¼ºÄáÆÏº´
  • acute infectious disease
    ±Þ¼º°¨¿°º´
  • adult disease
    ¼ºÀκ´
  • aircraft disease
    (¢¡aviator's disease) Ç×°øº´
  • alkali disease
    ¾ËÄ®¸®º´
  • allergic disease
    ¾Ë·¹¸£±âº´
  • aluminium dust disease
    ¾Ë·ç¹Ì´½°¡·çº´
  • alveoar hydatid disease
    ²Ê¸®ÇüÆ÷Ãæº´, ´Ù¹æÆ÷Ãæº´
  • arteriosclerotic cardiovascular disease
    µ¿¸Æ°æÈ­½ÉÀåÇ÷°üº´
  • arteriosclerotic heart disease
    µ¿¸Æ°æÈ­½ÉÀ庴
  • arthropod-borne viral disease
    ÀýÁöµ¿¹°¸Å°³¹ÙÀÌ·¯½ºº´
  • atherosclerotic heart disease
    Á×»ó°æÈ­½ÉÀ庴
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Degenerative disease
    ÅðÇ༺Áúȯ
  • Dego s disease
    µ¥°íº´.
  • Dejerine-Sottas disease
    µ¥Á¦¸°-¼ÚŸº´.
  • Dercums disease
    ´õÄĺ´
  • Detergent workers disease
    ¼¼Á¤Á¦Ãë±ÞÀÚÁúȯ
  • Devics disease=>optic neuromyelitis
    µ¥ºòº´
  • Di Guglielmos disease
    µð±¸±Û¸®¿¤¸ðº´, ÀûÇ÷º´¼º °ñ¼öÁõ.
  • Dorfman-Chanarin syndrome = neutral lipid storage disease
    Áß¼ºÁö¹æÃàÀûÁõ
  • Dowling-Degos disease = reticular pigmented anomaly of the flexures
    ±¼ÃøºÎ ¸Á»ó»ö¼ÒÀÌ»ó(Áõ)
  • Duhrings disease => dermatitis herpetiformis
    Æ÷Áø»ó ÇǺο°
  • Duncans disease .
    ´øÄ­¾¾º´
  • Eagles disease
    À̱۽ºº´
  • Eales disease
    ÀϽºº´
  • Ebola disease
    ¿¡º¼¶óº´
  • Ebola disease
    ¿¡º¼¶ó º´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • residual chromatin
    ¿°»öÁúÀÜ¿© (È£¿°±â¼º°ú¸³)
  • residual current
    ÀÜ·ùÀü·ù(íÑë§ï³êü).
  • residual cyst
    ÀÜ·ù³¶
  • residual cyst
    ÀÜ·ù³¶.
  • residual delirium
    ÀÜÀ缺 ¸Á»ó(íÑî¤àõØÍßÌ).
  • residual elengation
    ÀÜ·ù½ÅÀå(íÑë§ãßíå).
  • residual epilepsy
    ÀÜ·ù°£Áú(íÑë§ÊÖòð).
  • residual epilepsy
    ÀÜ·ù°£Áú(íÑë§ÊÖòð)
  • residual free chlorine
    À¯¸®ÀÜ·ù¿°¼Ò(·®)(ËôËöËöËôËçËÛ).
  • residual hearing
    ÀÜû
  • residual immunity
    ÀÜ¿©¸é¿ª(íÑæ®Øóæ¹).
  • residual lumen
    ÀÜ¿©³»°­
  • residual nitrogen
    ÀÜ¿©Áú¼Ò(íÑæ®òòáÈ).
  • residual nucleus
    ÀÜ·ù(»ý¼º)ÇÙ(íÑë§ ßæà÷ú·).
  • residual paralysis
    ÈÄ(À¯)¸¶ºñ.
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • rheumatic disease
    ·ù¸¶Æ¼½º¼ºÁúȯ
  • rheumatic heart disease
    ·ù¸¶Æ¼½º¼º½ÉÁúȯ
  • spirochetal disease
    ½ºÇÇ·ÎÇìŸÁúȯ
  • storage disease
    ÃàÀûÁõ
  • Tay-Sachs disease
    Å×ÀÌ-»è½ºº´
  • thromboembolic disease
    Ç÷Àü»öÀü¼ºÁúȯ
  • Tietzes disease+B701
    ƼÂź´
  • underlying disease
    ¿øÁúȯ, ±âÃÊÁúȯ
  • valvular disease
    ÆÇ¸·Áõ
  • valvular heart disease
    ÆÇ¸·¼º½ÉÁúȯ
  • wasting disease
    ¼Ò¸ðº´
  • Wilson's disease
    Àª½¼º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MCD   1) Minimal Change Disease
  2) Menstrual Cycle Day
MCL Minimal Change Disease
MEGD minimal euthyroid Graves disease
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
FRC Functional Residual Capacity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MED Minimal Erythema Dose
MEM Minimal Essential Medium
MIC Minimal Inhibition Concentration
MIC Minimal Inhibitory Concentration
MIC90 Minimal Inhibitory Concentration
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Bernhardt's disease
    º£¸¥Çϸ£Æ® º´
    µ¿ÀǾî=meralgia
  • Best's disease
    º£½ºÆ® º´
    µ¿ÀǾî=congenital macular degeneration.
  • black disease
    Èæ»ö º´
    ¾çÀÇ Àü¿°¼º ±«»ç¼º °£¿°. ¹Ì±¹, ¿À½ºÆ®·¹Àϸ®¾Æ¿¡¼­ÀÇ ¾çÀÇ Ä¡»çº´ÀÌ¸ç ¶§¶§·Î »ç¶÷¿¡°Ôµµ »ý±ä´Ù. °£ÀåÀÇ ±«»ç°¡ ±× Ư¡ÀÌ¸ç ³ëºñ±Õ¿¡ ÀÇÇÏ¿© ÀϾ´Ù.
  • bleeder's disease
    Ç÷¿ìº´
    ÃâÇ÷À» Àß ÀÏÀ¸Å°°Å³ª ÃâÇ÷ ¼ÒÁúÀÌ ÀÖ´Â Áúº´.
  • Blocq's disease
    ºí·Ï º´
    µ¿ÀǾî=astasia, abasia.
  • blood disease
    Ç÷¾× ÀÌ»ó
    µ¿ÀǾî=hemic disease.
  • bone disease
    °ñ Áúȯ
    µ¿ÀǾî=osteo
  • Bowen's disease
    º¸À¢ º´, º¸À¢ Áúȯ
    1. À¯¿øÇüÀÇ °æ°è. ¼±¸íÇÑ Èë°¥»ö ³»Áö °¥»öÀÇ ±¹¼ÒÀû º´º¯À» Çü¼ºÇÑ´Ù. ±¸°­ Á¡¸·ÀÇ Àû»ö, ¹é»ö ¹ÝÁ¡À¸·Î ¶Ñ·ÇÇÑ ºÒ±ÔÄ¢ÇÑ ¼ºÀåÀ» ÇÑ´Ù. °¡Çǰ¡ µ¤È÷¸é¼­ ¿ø½É»óÀ¸·Î È®´ëÇϴµ¥ Ç¥ÇÇ ³»¾ÏÀÇ »óŸ¦ À¯ÁöÇÏ¸ç ±âÀúÃþ¿¡ ÆÄ±«, Áõ½Ä, ÀüÀ̸¦ ³ªÅ¸³»´Â °ÍÀº »ó´çÈ÷ ÁøÇàÇÑ °æ¿ìÀÌ´Ù. Ä¡·á¹ýÀ¸·Î¼­´Â ÀýÁ¦, Ç×¾ÏÁ¦ ¿¬°í°¡ »ç¿ëµÈ´Ù. 2. ³»Àå ¾Ï°ú °ü·Ã ÀÖ´Â ºñħÀ±¼º ¾ÏÁ¾À¸·Î µå¹°°Ô ¹ß»ýÇÏ¸ç ³²¼º, ¿©¼º ¸ðµÎ ¼º±â¿¡ ¹ß»ýÇÑ´Ù. 3. »óÇdz»ÀÇ ¾Ç¼º Á¾¾çÀÌ´Ù. ¾Ç¼º ¼ºÀåÀº °Ç°­ÇÑ ±âÀú¸·°ú ÇÔ²² »óÇÇ¿¡ Á¦ÇѵȴÙ. ÇǺδ ¸î °³ÀÇ À¶±âµÈ Á¡À» µ¿¹ÝÇÑ Ã¤ ºÓ°Ô ³ªÅ¸³ª¸ç ºÎºÐÀûÀ¸·Î Àμ³ÀÌ Çü¼ºµÇ¾î ÀÖ°í ºÎºÐÀûÀ¸·Î Á¥¾î ÀÖ´Ù. Áß¾Ó¿¡ À§ÃàÀ̳ª ±Ë¾çÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 4. ºñ±³Àû µå¹® ÁúȯÀ¸·Î ³ëÃâ ¶Ç´Â ºñ³ëÃâ ºÎÀ§¿¡ »ý±æ ¼ö ÀÖ´Ù. º´º¯Àº ÀÛ°í
  • Brill-Zinsser disease
    Brill-Zinsser º´
    ¹ßÁøÆ¼Çª½º¿¡ °É·È´ø ȯÀÚ¿¡¼­ ¹ß»ýµÇ´Â Àç¹ßÇüÀÇ º´À¸·Î ¸®ÄÉÄ¡¾Æ±ÕÀº º´ÀÌ ³ªÀº ÈÄ¿¡µµ ¼ö ½Ê³â°£ Áõ»ó ¾øÀÌ ¸²ÇÁÀý ¼Ó¿¡ Á¸¼ÓÇÒ ¼ö ÀÖ´Ù.
  • Buergers disease
    ¹ö°Å º´
  • bullous disease
    ¼öÆ÷¼º Áúȯ
  • bullous skin disease
    ¼öÆ÷¼º ÇǺΠÁúȯ
  • calcific mitral disease
    ¼®È¸È­ ½Â¸ðÆÇ¸· Áúȯ
  • caloric disease
    °í¿Â º´
    °í¿Â¿¡ ³ëÃâµÇ¾î ³ªÅ¸³ª´Â Áúȯ.
  • Canavan's disease
    Ä«³ª¹Ý º´
    »ó¿°»öü ¿­¼º À¯ÀüÇÏ´Â ÁúȯÀ¸·Î ¾Æ½ºÆÄ¸£Å侯½Ç¶óÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
alpha chain disease A vague or indefinite term; could be used for alpha-heavy-chain disease (a lymphoplasma cell proliferative disease usually seen in Mediterranean men, characterised by intestinal involvement with steatorrhoea, often progressive with fatal outcome) or a thalassaemia (a genetic abnormality in the alpha globin chain of haemoglobin).
(05 Mar 2000)
altitude disease A condition that results from prolonged exposure to high altitude.
Symptoms include a continuous dry cough, shortness of breath, poor exercise tolerance, dizziness, headache, sleep difficulty, anorexia, confusion, fatigue and a rapid pulse.
Treatment includes the immediate movement to a lower altitude. Prophylaxis has been accomplished successfully with the use of acetazolamide (Diamox).
(27 Sep 1997)
alzheimer disease A degenerative organic mental disease characterised by progressive brain deterioration and dementia. The disease was originally described as dementia, presenile occurring in persons under the age of 65 (as opposed to dementia, senile with onset at or after 65); however, onset may occur at any age. There is no pathophysiological nor clinical distinction between the two stages of onset of alzheimer's. Women appear to be affected twice as frequently as men. It is characterised pathologically by the triad of senile plaques, neurofibrillary tangles, and neuropil threads.
(12 Dec 1998)
Alzheimer's disease <disease> A progressive, neurodegenerative disease characterised by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
The cause of nerve cell death is unknown but the cells are recognised by the appearance of unusual helical protein filaments in the nerve cells (neurofibrillary tangles) and by degeneration in cortical regions of brain, especially frontal and temporal lobes.
Alzheimer's disease is the most common cause of dementia.
(22 May 1997)
anaemia of chronic disease <disease> A form of anaemia which develops as the result of a long-term infection or illness. Chronic diseases can interfere with red blood cell production in addition to shortening red blood cell life span in the body.
Symptoms are largely due to the underlying disease. Haemoglobin and haematocrit are generally low. Iron studies may be low to normal. Red blood cell indices may usually normal.
(27 Sep 1997)
anarthritic rheumatoid disease Rheumatoid disease without arthritis.
(05 Mar 2000)
Anders' disease <disease> A disease accompanied by painful localised fatty swellings and by various nerve lesions. It is usually seen in women and may cause death from pulmonary complications.
(12 Dec 1998)
Andersen's disease Familial cirrhosis of the liver with storage of abnormal glycogen; glycogenosis due to deficiency of 1,4-alpha-glucan branching enzyme, resulting in accumulation of abnormal glycogen with long inner and outer chains in liver, kidney, muscle, and other tissues.
Synonym: Andersen's disease.
(05 Mar 2000)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
anti-glomerular basement membrane disease Glomerulonephritis, usually of a generalised proliferative crescent-forming histologic type with a rapidly progressive course, marked by circulating anti-gbm antibodies and linear deposits of immunoglobulin and complement along the glomerular basement membrane. When associated with pulmonary haemorrhage the condition is called goodpasture syndrome.
(12 Dec 1998)
aortoiliac occlusive disease Obstruction of the abdominal aorta and its main branches by atherosclerosis.
(05 Mar 2000)
apical interstitial lung disease <radiology> A radiological diagnosis where fibrosis is seen in the apices (upper sections) of the lungs.
Likely causes include: cystic fibrosis, ankylosing spondylitis, sarcoidosis, silicosis, eosinophlic granuloma, TB and fungus, particularly aspergillus infection.
(25 Jun 1999)
Aran-Duchenne disease A serious neurologic disease that results from the progressive degeneration of the motor neurons.
(27 Sep 1997)
asbestos lung disease <radiology> Pleural plaques, earliest finding, may be only evidence, parietal pleura, 15-20 yrs after exposure, calcified after ca. 30 yrs, asbestosis, interstitial lung disease, perihilar regions to lung bases, shaggy heart, no cavitation or progressive massive fibrosis as in silicosis, crocidolite (blue) form most carcinogenic, associated with: malignant pleural mesothelioma, peritoneal mesothelioma, GI-tract malignancy
(12 Dec 1998)
asherman disease <radiology> Uterine synechiae, linear, lucent defects in uterus on HSG, usually secondary to endometrial trauma (D&C, etc.)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pullet disease
    X;=BLUE COMB
  • rat-bite fever(disease)
    ¼­±³¿­
  • rheumatic disease
    ·ù¸ÓƼ½º¼º Áúȯ
  • social disease
    ¼ºº´
  • stress disease
    (ÀÚ±Ø,±äÀåÀ¸·Î ÀϾ´Ù´Â) ½ºÆ®·¹½ºº´
  • vocational disease
    Á÷¾÷º´
  • zymotic disease
    ¹ßÈ¿º´;¹ßÈ¿°¡ º´ÀÎÀ¸·Î ¿©°ÜÁ³´øsmallpoxµûÀ§
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á